European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - etanercept - arthritis, psoriatic; spondylitis, ankylosing; psoriasis - immunosuppressants - rheumatoid arthritis;juvenile idiopathic arthritispsoriatic arthritis;axial spondyloarthritis;plaque psoriasis;paediatric plaque psoriasis.

Canada - English - Health Canada

immunex corporation - etanercept; water - kit - 25mg; 1ml - etanercept 25mg; water 1ml - disease-modifying antirheumatic agents

Canada - English - Health Canada

immunex corporation - etanercept - solution - 50mg - etanercept 50mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

lupin pharma canada limited - etanercept - solution - 25mg - etanercept 25mg

Canada - English - Health Canada

lupin pharma canada limited - etanercept - solution - 50mg - etanercept 50mg

Canada - English - Health Canada

lupin pharma canada limited - etanercept - solution - 50mg - etanercept 50mg

United States - English - NLM (National Library of Medicine)

a-s medication solutions - etanercept (unii: op401g7ojc) (etanercept - unii:op401g7ojc) - enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (ra). enbrel can be initiated in combination with methotrexate (mtx) or used alone. enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (jia) in patients ages 2 and older. enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (psa). enbrel can be used with or without methotrexate. enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (as). enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (pso) who are candidates for systemic therapy or phototherapy. enbrel

United States - English - NLM (National Library of Medicine)

a-s medication solutions - etanercept (unii: op401g7ojc) (etanercept - unii:op401g7ojc) - enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (ra). enbrel can be initiated in combination with methotrexate (mtx) or used alone. enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (jia) in patients ages 2 and older. enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (psa). enbrel can be used with or without methotrexate. enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (as). enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (pso) who are candidates for systemic therapy or phototherapy. enbrel

United States - English - NLM (National Library of Medicine)

a-s medication solutions - etanercept (unii: op401g7ojc) (etanercept - unii:op401g7ojc) - enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (ra). enbrel can be initiated in combination with methotrexate (mtx) or used alone. enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (jia) in patients ages 2 and older. enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (psa). enbrel can be used with or without methotrexate. enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (as). enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (pso) who are candidates for systemic therapy or phototherapy. enbrel

Israel - English - Ministry of Health

dexcel ltd, israel - etanercept - solution for injection - etanercept 25 mg / 0.5 ml - etanercept - rheumatoid arthritis: nepexto is indicated for the treatment of active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate. nepexto can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis. nepexto, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function. psoriatic arthritis: treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease. plaque psoriasis: treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. paediatric plaque psoriasis: treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. juvenile idiopathic arthritis: treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. etanercept has not been studied in children aged less than 2 years. axial spondyloarthritis ankylosing spondylitis(as): treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. non-radiographic axial spondyloarthritis: treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids).